Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2009Thrombosis and Haemostasis

Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSara GastoldiMario Negri Institute for Pharmacological ResearchEDErica DainaFoundation for Innovative New DiagnosticsDBDaniela BelottiAzienda Ospedaliera San Gerardo

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gastoldi et al. (2009) studied this question.

synapsesocial.com/papers/6a911fcf57098c5b59c1abdfhttps://doi.org/10.1160/th07-12-0753
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report2005 · 48 citations
  2. 2Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab2005 · 46 citations
  3. 3Prognostic value of inhibitory anti‐ADAMTS13 antibodies in adult‐acquired thrombotic thrombocytopenic purpura2005 · 121 citations
  4. 4Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab2002 · 128 citations
  5. 5Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐132006 · 268 citations